Megaciflox Tablets
Megaciflox Tablets
Pharmaceutical
| Ingredients and content | Ciprofloxacin Hydrochloride 291mg (ciprofloxacin 250mg) |
| Efficacy · effect |
Effective strains Escherichia coli, Shigella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus (Indole positive & negative), Pseudomonas, Neisseria, Acinetobacter, Streptococcus, Chlamydia, Staphylococcus, Bacteroides Indication - Respiratory infection, community acquired infection pneumonia except acute bronchitis - Ear, nose, and throat infection (pharyngitis, tonsillitis, laryngitis, otitis externa, except preoperative use against bone-metastasized chronic otitis media and chronic cholesteatomatous otitis media) - Bacterial prostatitis, acute uncomplicated cystitis, acute pyelonephritis, complicated Urinary tract infection - Gonococcal cervicitis and gonococcal urethritis - Gastrointestinal infection - Biliary tract infection - Skin and soft tissue infection and wound - Bone, joint infection - Gynecologic infection (except vaginal infections) - Peritonitis - Dacryocystitis, hordeolum, anophthalmia |
| Usage · Dosage |
(tablets) Orally administer 250 to 500 mg of ciprofloxacin twice daily between meals in adults. Renal impairment : Refer to the product details |
| Period of use and storage method | 36 months from MFD, Well-closed container, Store at room temperature(1～30℃ ) |
| Packaging information | 30T/Bottle, 100T/Bottle, 300T/Bottle, 500T/Bottle |
